Niklas Klümper

Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy This study examines a modified progressive disease classification and its association with postprogression survival in patients treated with atezolizumab across various solid tumors.

Happy to share our manuscript titled 'Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy' published in JAMA Oncology!

@jama.com

jamanetwork.com/journals/jam...

27.12.2024 20:23 — 👍 5    🔁 0    💬 1    📌 0

Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy This study examines a modified progressive disease classification and its association with postprogression survival in patients treated with atezolizumab across various solid tumors.

Can patterns of progression on IO, inform future decisions?

-1377pts from 5 ph 3 trials used to create 3 PD risk levels
- low (⬆️existing lesions), intermediate (new lesions), high (both)
- risk score assoc w post-PD OS across tumors

Prognostic, so far #LCSM

jamanetwork.com/journals/jam...

26.12.2024 20:54 — 👍 23    🔁 9    💬 0    📌 0

Great review! NECTIN4 is an exciting target. More to come !
#cancer #jcoprecisionmedicine #bladdercancer #guoncology #biomarker

11.12.2024 09:10 — 👍 4    🔁 1    💬 0    📌 0

Awesome talk by @joshmeeks.bsky.social on trial design in NMIBC. Huge need to get away from single arm trials. #SUO24

05.12.2024 17:47 — 👍 18    🔁 4    💬 1    📌 3

Happy to share our study published @JCO_ASCO ! ascopubs.org/doi/full/10.12…

➡️Patients with mUC with NECTIN4 amplifications (app. 25%) show remarkable responses to single-agent EV, with a 96% ORR compared to 32% in non-amplified cases!

@ptarantinomd.bsky.social @markuseckstein3.bsky.social

11.12.2024 09:12 — 👍 5    🔁 1    💬 0    📌 0